"diabetic foot ulcers (dfus), affecting approximate- ly 6.3% of diabetics globally, are a leading cause of non-traumatic amputations. in india, 25% of the 62 million diabetic population develops dfus, resulting in around 100,000 leg amputations annually. the economic burden is significant, with treatment costs averaging 1,960 usd per patient, often beyond the reach of the average income earner. current standard-of-care (soc) treatments are inadequate, with limited availability of indigenously developed, cost-effective advanced dressings that can be scaled to meet the needs of a large population. human placental membranes, typically discarded as biomedical waste, offer a promising solution due to their anti-inflammatory, angiogenic, and growth factor-rich properties. clinical studies have shown that placental grafts can significantly accelerate the healing of chronic diabetic ulcers, reducing recov- ery time. however, india faces challenges in adopt- ing placental allografts clinically due to high costs and limited availability of off-the-shelf grafts. to bridge these gaps, an innovative lyopreserved, acellular placental graft has been developed, currently at technology readiness level (trl) 5/6. the tissue processing technology used includes decellularization, trehalose lyopreservation, and lyophilization, preserving the graft's extracellular matrix and mechanical integrity. a unique combination of non-ionic surfactants ensures effective decellularization without damaging the membrane, while trehalose stabilizes protein content during lyophilization. the final product is sterilized through gamma irradiation, ensuring clinical safety. this advanced graft serves as a platform for re- generative therapies, offering an affordable, scalable, and effective solution for chronic wound care, particularly in diabetic populations. its large-scale manufacturing potential makes it a critical innovation in the medical device sector, addressing the unmet clinical need for accessible and bioactive wound-healing products."